我国医院高危药品风险控制责任主体及其诉求研究

Study on Liability Subjects and Demands of Risk Control of High-risk Drugs in Hospitals in China

目的界定我国高危药品风险控制责任主体及其对高危药品风险管理的诉求,为更科学、有效地开展高危药品风险管理提供参考。方法通过文献研究初步确定高危药品风险管理相关责任主体,依据米切尔评分原则设计调查量表,并通过两轮专家咨询,确定高危药品风险控制责任主体。根据专家在风险控制责任、风险控制参与度、风险处置能力三个维度的评分情况,计算责任指数并对其分类。通过现场问卷调查明确责任主体对我国高危药品风险管理上的诉求。结果专家咨询界定11个医院内部高危药品风险控制责任主体;确定医院管理人员、医生、护士、药师、质量控制部门为核心责任主体;医务人员对降低高危药品风险的诉求是需要定期的高危药品知识培训,其次是药师协助指导高危药品用药。结论加强医务人员高危药品知识培训,积极推进药师参与高危药品管理和使用,有利于我国高危药品的安全用药。

Objective This article aims to define the liability subjects of risk control of high-risk drugs and their demands of each responsible subject on the risk management of high-risk drugs,so as to provide a reference for more scientific and effective risk management of high-risk drugs.Methods Through the literature research,the relevant responsible subjects for high-risk drugs management were initially determined.The survey scale was designed according to the Mitchell scoring principle,and the liability subjects of risk control of high-risk drugs was determined through two rounds of expert consultation.According to the scores of experts in the three dimensions of risk control responsibility,risk control participation,and risk handling ability,the responsibility index was calculated and classified.On-site questionnaire clarified the demands of the liability subjects for the risk management of high-risk drugs in China.Results Through expert consultation,11 liability subjects of high-risk drug control in hospitals were defined.Hospital management personnel,doctors,nurses,pharmacists,and quality control departments were determined as the core liability subjects;Medical staff's demand for reducing the risk of high-risk drugs was that they required regular high-risk drug knowledge training,followed by pharmacists’assistance in guiding the use of high-risk drugs.Conclusion Strengthening the training of high-risk drugs for health works and actively promoting the participation of pharmacists in the management and use of high-risk drugs are beneficial to the safe use of high-risk drugs in China.